Table 4.
Prognostic Factors of disease-free survival (DFS) in patients with AML after allo-SCT
|
Variable
|
Survival time
|
Univariate
|
Multivariate
|
|||
|---|---|---|---|---|---|---|
| Mean ± SD (Months) |
HR (95% CI) |
P-value | HR (95% CI) |
P-value | ||
| Sex | Male | 51.95 ± 6.62 | 0.91 (0.51-1.64) | 0.76 | ||
| Female | 42.87 ± 4.94 | 1 | ||||
| Age group of patients | ≤ 30 | 50.60 ± 6.79 | 1.06 (0.59-1.91) | 0.84 | ||
| > 30 | 50.13 ± 6.11 | 1 | ||||
|
Diseases status at
transplant |
CR1 | 51.33 ± 4.63 | 0.64 (0.15-2.65) | 0.54 | ||
| CR2 | 18.36 ± 9.64 | 1 | ||||
| WBC (×10 8 /ml) | <5 | 65.15 ± 5.82 | 1 | 1 | ||
| 5-10 | 23.21 ± 6.80 | 2.9 (1.26-6.67) | 0.02* | 0.39(0.15-1.00) | 0.07 | |
| >10 | 21.50 ± 6.77 | 3.57 (1.69-7.56) | 0.001* | 0.86 (0.28-2.62) | 0.05 | |
| Donor relative | Sibling | 52.73 ± 4.75 | 0.56 (0.23-1.32) | 0.18 | ||
| Non- sibling | 14.63 ±4.61 | 1 | ||||
| Age group of donors | ≤ 30 | 55.82 ± 6.97 | 0.82 (0.45-1.52) | 0.53 | ||
| > 30 | 43.88 ± 5.43 | 1 | ||||
|
Sex of donor –
recipient |
F-F | 41.56 ± 7.17 | 1.35 (0.58-3.13) | 0.48 | ||
| F-M | 46.82 ± 9.59 | 1.28 (0.54-3.0) | 0.58 | |||
| M-F | 42.36 ± 6.37 | 1.14 (0.49-2.64) | 0.76 | |||
| M-M | 57.35 ± 8.39 | 1 | ||||
| AML | M3 | 20.55 ± 7.49 | 1.15 (0.28-4.76) | 0.84 | ||
| Non-M3 | 50.99 ± 4.46 | 1 | ||||
|
Different types of
ALM |
M2 | 22.03 ± 5.89 | 0.30 (0.13-0.68) | 0.04* | 0.43 (0.17-1.11) | 0.08 |
| M4 | 61.54 ± 6.37 | 1 | 1 | |||
| M5 | 52.84 ± 8.14 | 0.51 (0.23-1.10) | 0.08 | 0.57 (0.26-1.27) | 0.17 | |
Acute graft-versus-host diseases (aGVHD), chronic graft-versus-host diseases (cGVHD), first and second complete remission (CR1, CR2)